GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Precision BioSciences Inc (NAS:DTIL) » Definitions » Asset Turnover

Precision BioSciences (Precision BioSciences) Asset Turnover : 0.04 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Precision BioSciences Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Precision BioSciences's Revenue for the three months ended in Dec. 2023 was $7.04 Mil. Precision BioSciences's Total Assets for the quarter that ended in Dec. 2023 was $162.06 Mil. Therefore, Precision BioSciences's Asset Turnover for the quarter that ended in Dec. 2023 was 0.04.

Asset Turnover is linked to ROE % through Du Pont Formula. Precision BioSciences's annualized ROE % for the quarter that ended in Dec. 2023 was -271.91%. It is also linked to ROA % through Du Pont Formula. Precision BioSciences's annualized ROA % for the quarter that ended in Dec. 2023 was -40.20%.


Precision BioSciences Asset Turnover Historical Data

The historical data trend for Precision BioSciences's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Precision BioSciences Asset Turnover Chart

Precision BioSciences Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial 0.12 0.13 0.64 0.11 0.25

Precision BioSciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.04 0.10 0.08 0.04

Competitive Comparison of Precision BioSciences's Asset Turnover

For the Biotechnology subindustry, Precision BioSciences's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Precision BioSciences's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Precision BioSciences's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Precision BioSciences's Asset Turnover falls into.



Precision BioSciences Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Precision BioSciences's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=48.727/( (238.169+159.781)/ 2 )
=48.727/198.975
=0.24

Precision BioSciences's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=7.038/( (164.344+159.781)/ 2 )
=7.038/162.0625
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Precision BioSciences  (NAS:DTIL) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Precision BioSciences's annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-65.156/23.962
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-65.156 / 28.152)*(28.152 / 162.0625)*(162.0625/ 23.962)
=Net Margin %*Asset Turnover*Equity Multiplier
=-231.44 %*0.1737*6.7633
=ROA %*Equity Multiplier
=-40.20 %*6.7633
=-271.91 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Precision BioSciences's annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-65.156/162.0625
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-65.156 / 28.152)*(28.152 / 162.0625)
=Net Margin %*Asset Turnover
=-231.44 %*0.1737
=-40.20 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Precision BioSciences Asset Turnover Related Terms

Thank you for viewing the detailed overview of Precision BioSciences's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Precision BioSciences (Precision BioSciences) Business Description

Traded in Other Exchanges
Address
302 East Pettigrew Street, Dibrell Building, Suite A-100, Durham, NC, USA, 27701
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
Executives
J. Jefferson Smith 10 percent owner C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
Alan List officer: Chief Medical Officer C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, DURHAM NC 27701
Michael Amoroso director, officer: President and CEO 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Dario Scimeca officer: General Counsel C/O PRECISION BIOSCIENCES, INC., 302 E. PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
John Alexander Kelly officer: Interim CFO C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Pharma Ag Novartis 10 percent owner LICHTSTRASSE 35, CH-4002, BASEL V8
Ag Novartis 10 percent owner LICHTSTRASSE 35, BASEL V8 CH 4056
Derek Jantz director, 10 percent owner, officer: Chief Scientific Officer C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
Melinda Brown director 10 HUDSON YARDS, NEW YORK NY 10001
Shari Lisa Pire director C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, DURHAM NC 27701
Samuel C. Wadsworth director C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
David S. Thomson officer: Chief Development Officer C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
Stanley Frankel director C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, DURHAM NC 27701
Matthew R. Kane director, 10 percent owner, officer: President and CEO C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
Shane Barton officer: VP & Corporate Controller C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, DURHAM NC 27701

Precision BioSciences (Precision BioSciences) Headlines